Opendata, web and dolomites

NEUREKA SIGNED

A smart, hybrid neural-computo device for drug discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEUREKA project word cloud

Explore the words cloud of the NEUREKA project. It provides you a very rough idea of what is the project "NEUREKA" about.

proof    computational    shift    dendritic    levels    multiple    stem    paradigm    innovative    introduces    tree    complementing    network    effect    replicate    drive    drugs    circuits    nanoelectrodes    axonal    burden    registered    assays    human    economical    synaptic    locations    diseases    cultured    optimize    deficits    molecular    repeated    societal    loop    pathological    physiological    functions    transmission    discovery    suffers    failures    reproducing    incurable    culture    excitability    neurological    monitor    cell    fed    simulated    standard    functional    emerge    candidate    drug    pluripotent    quantification    closing    compounds    neuronal    neurodegeneration    neureka    accuracy    subcellular    exhibiting    unprecedented    faithfully    branches    contact    models    exacerbating    synapses    networks    pathology    mediate    brain    neural    soma    whereby    simulate    akin    neurons    hybrid    replication    lack    cellular    shortcoming    disease    ipsc    back    alzheimer    candidates    biological    vitro    dysfunction    population   

Project "NEUREKA" data sheet

The following table provides information about the project.

Coordinator
IDRYMA TECHNOLOGIAS KAI EREVNAS 

Organization address
address: N PLASTIRA STR 100
city: IRAKLEIO
postcode: 70013
website: www.forth.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 2˙776˙705 €
 EC max contribution 2˙776˙704 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2023-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) coordinator 753˙250.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 756˙452.00
3    MAXWELL BIOSYSTEMS AG CH (ZURICH) participant 466˙562.00
4    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 465˙440.00
5    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 335˙000.00

Map

 Project objective

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the functional assessment of candidate compounds at multiple levels: from synapses to neuronal circuits. NEUREKA introduces an innovative, hybrid technology, whereby detailed, computational neuronal networks simulate dysfunction and drive cultured neurons to replicate in-brain disease conditions. Nanoelectrodes mediate the transmission between simulated and biological neurons. Akin to real synapses, nanoelectrodes contact cultured neurons at subcellular locations across the dendritic tree, soma and axonal branches, allowing to control and monitor neural activity with unprecedented accuracy. Biological neuronal responses registered by nanoelectrodes are fed back to simulated neurons, closing the loop and enabling control of activity states across the hybrid population. Complementing molecular deficits already present in culture models of a disease, computational models enable replication of both molecular and physiological deficits of neurodegeneration in vitro. Cultured neurons are driven towards pathological excitability states where deficits emerge, so as to optimize quantification of the impact of drugs, going well beyond standard cellular assays. A proof-of-concept will be provided for Alzheimer’s disease, using human induced pluripotent stem cell (iPSC)-derived neurons exhibiting the pathology. NEUREKA will be used to demonstrate the effect of drug candidates across synaptic, neuronal and network functions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUREKA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUREKA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

cFLOW (2019)

Coherent ultraFast Long Wave infrared communications

Read More